Efficacy and Safety of Itolizumab in COVID-19 Complications: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Efficacy and Safety of Itolizumab in COVID-19 Complications (NCT04475588), a randomized phase 2 study. The primary outcome is One-month Mortality Rate Between the Two Arms.

2. Clinical Question

The clinical question is comparative: the registry records a randomized, parallel-group trial of itolizumab plus BSC against BSC alone. Its primary endpoint concerns a fatal outcome within the specified follow-up period, rather than a change in symptoms, laboratory measures, or time to an event. The posted comparison estimates the difference in the proportion with the outcome between the two arms.

The trial also lists secondary outcomes concerning absolute lymphocyte count, biomarkers IL-6 and TNF-a, the PaO2/FiO2 ratio, and radiological response. Those measures address different aspects of disease status and are not interchangeable with mortality. They may provide complementary context, but the primary question remains the comparison of one-month mortality.

The registry record describes the trial as phase 2 and open label, with no masking. It does not report detailed eligibility criteria, baseline characteristics, or the clinical criteria used to determine whether participants met the outcome definition. Those omissions limit how specifically the trial population and endpoint assessment can be characterized.

3. Trial Design

The registry describes NCT04475588, titled “Efficacy and Safety of Itolizumab in COVID-19 Complications,” as a randomized, parallel, two-arm, open-label phase 2 trial. Biocon Limited is listed as the sponsor. The recorded enrollment is 32. The trial status is completed, with a start date of 2020-05-01 and primary completion date of 2020-07-07.

Arm A received itolizumab IV infusion plus best supportive care, while Arm B received best supportive care. The registry gives primary-outcome arm denominators of 20 for Arm A and 10 for Arm B. These are the denominators attached to the posted primary endpoint results. The registry's enrollment figure is 32, and it does not explain the relationship between that figure and the primary-outcome denominators. Arm descriptions beyond the intervention names are not reported in the registry record.

Random assignment is stated, but the method used to generate the allocation sequence, any allocation concealment procedures, and the allocation ratio are not reported in the registry record. The study is explicitly open label and masking is listed as none. The registry therefore does not describe blinded treatment assignment or blinded outcome assessment.

The stated timeframe for the primary endpoint is one month, defined in the registry as a fatal outcome event by Day 30. The record lists 15 outcome measures and four posted secondary outcomes. It does not report a detailed protocol, trial locations, participant flow, or the full schedule of study assessments. The posted safety denominators differ from those for the primary endpoint in Arm A, and the record does not explain the relationship between the outcome-specific denominators.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as One-month Mortality Rate Between the Two Arms, measured over One-month.

The primary endpoint is the one-month mortality rate between the two arms. The registry defines this as the proportion of patients who met a fatal outcome event by Day 30. In the posted results, the endpoint is expressed as a count of participants with the event within each arm. It is therefore a binary outcome at the participant level: each participant either met the stated event definition or did not.

Mortality is used as a direct clinical outcome because it records whether a fatal event occurred during the specified follow-up period. Comparing the proportions between randomized arms provides an estimate of the absolute difference in observed event risk. That estimate is interpretable in the context of the registry's endpoint definition and follow-up window; it does not, by itself, describe when an event occurred within the window or account for other outcomes.

The record gives the event counts and denominators used for the primary comparison, along with a risk-difference estimate and confidence interval. It does not report additional details about how fatal outcomes were adjudicated, whether outcome information was complete for every randomized participant, or how missing endpoint data were handled. Those details matter when assessing the meaning and reliability of a binary endpoint, particularly when outcome denominators do not match the registry's enrollment figure.

7. Results Posted in the Registry

• Arm A - Itolizumab + BSC: 0.0% (0/20) versus 30.0% (3/10) on control; risk difference -30.0 percentage points (95% CI -58.4 to -1.6); unadjusted two-proportion z-test p = 0.010.

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Number and Percentage of Patients With Radiological Response

• Endpoint type: Binary: the number of participants with the event, compared as proportions.
• Test: Unadjusted two-proportion z-test, with a Wald 95% confidence interval for the risk difference.
• Result:
  • Arm A - Itolizumab + BSC: 45.0% (9/20) versus 10.0% (1/10) on control; risk difference 35.0 percentage points (95% CI 6.3 to 63.7), risk ratio 4.50 (0.66–30.74); unadjusted two-proportion z-test p = 0.055.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Arm A - Itolizumab + BSC and the control. The interval gives the range of effects that remain compatible with the data.

The registry lists secondary outcomes covering absolute lymphocyte count, IL-6 and TNF-a biomarkers, the PaO2/FiO2 ratio, and radiological response. These outcomes span laboratory, physiological, and imaging measures, so they address distinct dimensions of the clinical picture rather than repeating the mortality endpoint. The registry reports 15 outcome measures overall and four posted secondary outcomes, but does not provide the full set of secondary results in the record.

The posted radiological-response comparison has an observed risk difference of 0.35, with a 95% confidence interval from 0.064 to 0.637 and an unadjusted p-value of 0.055. This is a different endpoint from one-month mortality and should not be treated as confirmation or contradiction of the primary result. A result on one outcome does not determine the result on another, particularly when the outcomes measure different aspects of illness and have different timeframes or assessment processes.

Secondary results are generally less conclusive when many outcomes are examined without an adjustment strategy. Testing multiple outcomes increases the chance that some results may appear notable by chance. The registry does not report whether multiplicity was addressed, whether secondary outcomes were prioritized, or whether any secondary analyses were prespecified. The posted p-value is unadjusted, so it should be read as a nominal result rather than as evidence that accounts for the full set of outcomes examined.

The secondary outcomes may add context, but they carry less weight than a clearly prespecified primary analysis when their analysis plan and multiplicity handling are unknown. Their interpretation also depends on completeness, measurement definitions, and analysis populations, details that are not reported in the registry record. The overall pattern cannot be fully assessed from the posted secondary information alone.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Mean Change From Baseline of Absolute Lymphocyte Count
• Biomarkers (IL-6, TNF-a)
• Mean PaO2 (Partial Pressure of Oxygen) / FiO2 (Fraction of Inspired Oxygen, FiO2) Ratio (or P/F Ratio)
• Number and Percentage of Patients With Radiological Response

9. Statistical Interpretation

10. Statistical Methods Explained

The registry presents a binary primary outcome: whether each participant met the one-month fatal-outcome definition. For a binary outcome, the observed event proportion is the number of participants with the event divided by the outcome denominator for that arm. The primary comparison is expressed as a risk difference, which subtracts one arm's event proportion from the other. A risk difference of zero corresponds to equal observed proportions; a negative estimate in this comparison indicates a lower observed proportion in the itolizumab plus BSC arm than in the BSC arm.

The posted estimate is -0.3. Its 95% confidence interval ranges from -0.584 to -0.016. A confidence interval gives a range of values compatible with the observed data under the method's assumptions. It expresses sampling uncertainty in the estimated difference; it is not a range containing a fixed percentage of individual outcomes, nor does it account automatically for design or reporting limitations. The interval excludes zero, but the width indicates that the exact size of the underlying difference is imprecisely estimated.

The registry also reports an unadjusted p-value of 0.01 for the primary comparison. In general, a p-value is calculated under a null hypothesis and a statistical model, and measures how surprising the observed data would be, or data more extreme, if that null model were correct. It does not quantify clinical importance or the probability that the null hypothesis is true. The specific test and any adjustment strategy are not reported in the registry record, so the p-value should be treated as the posted unadjusted result rather than attributed to a particular named method.

Randomization is intended to support a fair comparison by assigning participants to arms independently of the treatment choice. However, the registry does not report how the random sequence was generated or concealed. The study was open label, so participants and study personnel were not masked according to the record. Whether outcome assessment was blinded is not reported in the registry record. These details can matter when measurements or decisions may be influenced by knowledge of assigned treatment.

What does a risk difference communicate?

A risk difference describes an absolute contrast in event proportions, not a relative change. It is often useful because it directly compares the frequency of the endpoint between arms. Its interpretation depends on the endpoint definition, time window, and populations represented in the denominators. It should not be translated into a different measure by mental arithmetic; the posted risk-difference estimate and interval are the reported comparison.

Why does the event count matter?

Binary outcomes with few observed events can yield unstable estimates. When the event count is low, changing the outcome status of a participant can noticeably alter the observed arm proportions. This is a general property of sparse binary data, not evidence that any particular participant was misclassified. The registry reports 0 events in the itolizumab plus BSC arm and 3 in the BSC arm for the primary endpoint. The small event count is an important reason to avoid treating the estimate as precise.

How should the planning illustration be read?

The registry includes a planning illustration derived from the observed radiological-response effect, not from the trial's own design. It assumes a two-sided significance level of 0.05, equal allocation, and a normal approximation, with the detectable effect set to a stated fraction of the observed effect. The illustration gives participants per arm for 80% and 90% power under those assumptions. For 100% of the observed effect, the figures are 25 participants per arm for 80% power and 33 for 90% power. For 75% of the observed effect, they are 40 and 53; for 50% of the observed effect, they are 77 and 103.

These figures are hypothetical planning illustrations. They are not observed power, do not describe the actual trial's design justification, and do not establish that the trial was sized according to these assumptions. The protocol's sample-size justification and the assumptions used to plan the actual trial are not reported in the registry record. Observed effects used for planning can be unstable, particularly when the original study is small, so the illustration should not be taken as a guarantee of what a future study would detect.

The record's outcome and analysis reporting also limits methodological interpretation. It lists 15 outcome measures and records 0 analyses, while posting outcome results and a primary comparison. The statistical model, confidence-interval procedure, missing-data method, and analysis population are not reported in the registry record. Without those details, the reported figures can be described and their general meaning explained, but the full analysis cannot be independently reconstructed from the registry information alone.

11. Confidence Intervals and Precision

The primary risk-difference estimate is -0.3, with a 95% confidence interval from -0.584 to -0.016. The interval excludes zero, but spans a broad range of possible differences. It therefore supports a direction for the observed contrast while leaving uncertainty about its magnitude. The interval does not eliminate concerns about the small event count, the outcome denominators, or the way participants entered the analysis.

Precision depends in part on how much information the data contain. The primary results include 0 events in one arm and 3 in the other, with denominators of 20 and 10, respectively. Sparse events provide limited information about the underlying event proportions. In this setting, the estimate can be sensitive to the outcome status of individual participants. The confidence interval is an expression of statistical uncertainty under the calculation method; it does not address unreported features of trial conduct or outcome ascertainment.

The registry's enrollment figure is 32, whereas the primary outcome denominators are 20 and 10. The registry record does not explain the relationship between enrollment and the endpoint denominators. It also does not report how missing outcome data were handled or whether the analysis included all randomized participants. These gaps make it difficult to assess whether the interval reflects the full randomized population or a subset.

Confidence intervals should not be read as guarantees that the true value lies in the displayed range, nor do they measure the probability of replication. They describe uncertainty associated with an estimate under statistical assumptions. The specific interval method is not reported in the registry record. Taken together, the posted interval and sparse events call for a cautious reading: the comparison is informative about the trial's observed data, but the exact effect remains uncertain.

12. Multiplicity, Missing Data and Analysis Populations

The registry record does not report a multiplicity strategy for the primary and secondary outcomes. This leaves unclear whether the primary endpoint was the sole confirmatory test, whether secondary outcomes were tested as a family, or whether any adjustment to account for multiple comparisons was applied. The posted secondary comparison is unadjusted. When several outcomes are examined, unadjusted p-values do not control the overall chance of a false-positive finding across the full set of analyses. This is a general statistical concern, not a claim that any particular reported result is false.

Missing-data procedures and analysis populations are also not reported in the registry record. The record does not say whether the primary comparison used an intention-to-treat population, a per-protocol population, or another defined group. It does not describe imputation, exclusion criteria for analysis, or sensitivity analyses for missing outcomes. These omissions make it difficult to judge whether missingness could have influenced the estimated comparison.

The registry records enrollment of 32, while the primary endpoint denominators are 20 and 10. Safety denominators are 22 and 10. These figures refer to different posted outcome contexts, and the record does not explain the differences or provide participant-flow details. It would be inappropriate to assume that the denominators reflect the same population or that a particular number of participants had missing data. The reasons for any differences are not reported in the registry record.

The primary outcome definition sets a one-month period ending at Day 30, but the record does not describe how outcomes were ascertained or adjudicated, or how participants without complete follow-up were handled. It also does not report interim analyses, stopping rules, or a detailed statistical analysis plan. Without these details, the posted estimates can be summarized, but the risk of bias from missing outcomes or analysis choices cannot be fully evaluated.

13. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 1% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: lower respiratory tract infection (20.0%), respiratory failure (20.0%), acute respiratory distress syndrome (20.0%), pericardial effusion due to underlying hypothyroidism (4.5%), anaphylactic reaction (4.5%).

The safety results should be read as descriptive counts with outcome-specific denominators. Serious adverse events were reported for 3 of 22 participants in the itolizumab plus BSC group and 3 of 10 in the BSC group. Other adverse events were reported for 18 of 22 and 4 of 10, respectively. The record also reports deaths of 1 and 3 in the two groups. These safety figures are separate from the primary endpoint denominators, and the registry does not explain the difference in denominators.

The most frequently listed serious adverse event terms include lower respiratory tract infection, respiratory failure, and acute respiratory distress syndrome, each reported as 20.0%. Other listed terms include pericardial effusion due to underlying hypothyroidism, anaphylactic reaction, and infusion related reaction, each reported as 4.5%. These percentages describe entries in the registry; the record does not provide additional detail about event timing, severity grading, relatedness to treatment, or whether categories could overlap.

Safety counts do not establish that an event was caused by an intervention, and they should not be interpreted as direct comparative estimates without details of collection and coding. The open-label design and limited size also constrain comparisons. The posted figures describe what the registry records, not a complete characterization of comparative safety.

14. What the Result Does, and Does Not, Mean

The primary results show a lower observed one-month fatal-outcome proportion in the itolizumab plus BSC arm than in the BSC arm, with a risk-difference estimate of -0.3. The 95% confidence interval ranges from -0.584 to -0.016, and the unadjusted p-value is 0.01. These statistics describe the trial's observed comparison and the uncertainty calculated for it. They do not, on their own, establish the size of an effect in a broader population or the probability that the result will recur.

The findings do not demonstrate that the intervention caused the observed difference. Randomization supports comparative inference, but the small event count, open-label design, absence of reported analysis details, and unexplained differences between enrollment and outcome denominators all limit confidence in broader conclusions. Important information about participant characteristics, outcome ascertainment, missing data, and the analysis population is not reported in the registry record.

The primary endpoint is limited to a fatal outcome by Day 30. It does not describe longer-term outcomes or capture every aspect of disease course. Secondary laboratory, physiological, and radiological measures address different questions and should not be substituted for mortality. Their interpretation is additionally limited by the absence of a reported multiplicity plan and complete secondary results.

The registry results therefore support a restrained statement: the posted primary comparison favored the itolizumab plus BSC arm in this trial, while uncertainty and reporting gaps remain substantial. The data should not be read as medical advice, as proof of benefit or lack of benefit, or as a definitive estimate applicable to patients outside the trial. Further interpretation would require details of the protocol, participant flow, analysis methods, and complete outcome reporting, which are not reported in the registry record.

15. Why This Trial Matters Statistically

This trial is statistically noteworthy because its primary endpoint is a clinically direct binary outcome, but only a small number of fatal events are posted. A risk-difference estimate can make the arm contrast easy to interpret, yet sparse events make that estimate particularly sensitive to individual outcomes. The interval communicates some of this uncertainty and should be considered alongside the point estimate rather than replaced by a binary reading of the p-value.

The contrast between randomized assignment and the available outcome denominators also matters. The registry records enrollment of 32, while the primary endpoint results use denominators of 20 and 10. Because the participant flow and analysis population are not explained, readers cannot determine from the record how enrollment translated into the analyzed endpoint data. That reporting gap is relevant to reproducibility and to judging possible selection effects.

The trial also illustrates why primary and secondary findings should be kept distinct. Mortality, biomarkers, physiological measures, and imaging outcomes capture different constructs. If multiple outcomes are assessed, unadjusted secondary comparisons may be exploratory, particularly when no multiplicity plan is reported. The radiological-response result and the mortality result should therefore be interpreted as separate pieces of evidence, not as interchangeable tests of one claim.

Finally, the planning illustration is based on the observed secondary effect and explicit hypothetical assumptions; it is not the trial's own sample-size rationale or a measure of observed power. Keeping planning calculations separate from trial results prevents a common misreading of retrospective illustrations. Overall, the registry provides a useful example of how effect estimates, uncertainty, outcome definitions, denominator reporting, and analysis transparency jointly shape statistical interpretation.

16. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several limitations specific to this trial constrain interpretation beyond the uncertainty captured by the primary confidence interval. The study is described as open label, and the registry lists masking as none. It does not report whether outcome assessment was blinded. Knowledge of treatment assignment could potentially influence assessments or clinical decisions, although the record does not establish that this occurred.

The primary endpoint results use denominators of 20 and 10, while the registry records enrollment of 32. The safety results use denominators of 22 and 10. The registry does not report a participant-flow account, reasons for differences in denominators, or the number of participants with complete follow-up. This prevents assessment of how the analyzed groups relate to enrollment and whether missing outcome information could have affected the comparisons.

The event count for the primary endpoint is small. The estimate may therefore be sensitive to individual outcomes, and the confidence interval remains broad. The registry does not report the statistical test or interval method, missing-data procedures, analysis population, allocation concealment, or outcome adjudication process. It also does not report whether there were interim analyses or a prespecified multiplicity strategy.

Generalizability is hard to assess because detailed eligibility criteria, baseline characteristics, and trial locations are not reported in the registry record. Secondary results are incomplete, and the registry does not describe the status or results of every listed measure. These limitations do not negate the posted results; they define what can and cannot be concluded from the registry record alone.

17. Related Tutorials

18. Related Statistical Calculators

19. Sources

• ClinicalTrials.gov: Efficacy and Safety of Itolizumab in COVID-19 Complications — NCT04475588.
• Registry record last updated 2021-06-14; status last verified 2021-06.
• Results first posted 2021-05-20.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

20. Record Summary

NCT04475588 is a completed, randomized, open-label, parallel, phase 2 trial sponsored by Biocon Limited. It compared itolizumab IV infusion plus best supportive care with best supportive care for COVID-19 complications. The recorded enrollment is 32. The trial started on 2020-05-01, and primary completion was recorded as 2020-07-07.

The primary outcome was one-month mortality, defined as a fatal outcome event by Day 30. The posted comparison reports 0 events among 20 participants in the itolizumab plus BSC arm and 3 among 10 in the BSC arm, with a risk difference of -0.3, a 95% confidence interval from -0.584 to -0.016, and an unadjusted p-value of 0.01. The registry also lists secondary outcomes and safety results.

Interpretation is limited by sparse primary events, open-label conduct, incomplete reporting of analysis methods and missing-data handling, and unexplained differences between enrollment and outcome denominators. The registry record does not provide the information needed to resolve these limitations.